Alan Colman Net Worth

The estimated Net Worth of Alan Colman is at least $112 Tisíc dollars as of 22 November 2016. Alan Colman owns over 5,000 units of VolitionRX Ltd stock worth over $111,630 and over the last 10 years he sold VNRX stock worth over $0. In addition, he makes $0 as Independent Director at VolitionRX Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Alan Colman VNRX stock SEC Form 4 insiders trading

Alan has made over 4 trades of the VolitionRX Ltd stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of VNRX stock worth $15,000 on 22 November 2016.

The largest trade he's ever made was exercising 100,000 units of VolitionRX Ltd stock on 29 March 2016 worth over $50,000. On average, Alan trades about 4,527 units every 32 days since 2014. As of 22 November 2016 he still owns at least 159,699 units of VolitionRX Ltd stock.

You can see the complete history of Alan Colman stock trades at the bottom of the page.

Alan Colman biography

Dr. Alan Colman serves as Independent Director of the Company. Dr. Colman served as a Director of Singapore Volition from April 1, 2011 to December 15, 2015 and currently serves as Chairman of the Scientific Advisory Board of Singapore Volition, a position he has held since April 5, 2011. Dr. Colman received a BA (1971), MA (1975) and PhD (1975) from Oxford University. Dr. Colman is currently an Associate at the Harvard University Department of Stem Cell and Regenerative Biology. Until its acquisition by Vertex Pharmaceuticals in October 2019, he served on the Scientific Advisory Board of Semma Therapeutics, Inc., a stem cell therapy company based in Cambridge, Massachusetts, a position he held since December 2014. From 2007 to 2013, Dr. Colman served as the Executive Director of the Singapore Stem Cell Consortium. Concurrently, Dr. Colman was Professor of Regenerative Medicine at King’s College, London, U.K., from 2008 to 2009. Prior to joining the A*STAR Singapore Stem Cell Consortium, Dr. Colman was Chief Scientific Officer and then Chief Executive Officer for the Singaporean human embryonic stem cell company, ES Cell International from 2002 to 2007. Dr. Colman was the research director at PPL Therapeutics in Edinburgh, U.K., from the late 1980s until 2002, where he was responsible for leading PPL’s research program strategy, also playing a role in PPL’s financing rounds, culminating in its listing on the London Stock Exchange in 1996. PPL attracted considerable media attention because of its participation in the technique of somatic nuclear transfer that led to the world’s first sheep cloned from an adult cell, Dolly, in 1996. Dr. Colman had a successful university career in the Universities of Oxford, Warwick, Birmingham (where he was Professor of Biochemistry) and London (as mentioned above). None of the above companies or organizations is a parent, subsidiary or other affiliate of the Company. Dr. Colman’s main current interest is the development of human disease models using induced pluripotent stem cell

How old is Alan Colman?

Alan Colman is 71, he's been the Independent Director of VolitionRX Ltd since 2011. There are 2 older and 19 younger executives at VolitionRX Ltd. The oldest executive at VolitionRX Ltd is Dr. Martin Charles Faulkes Ph.D., 77, who is the Exec. Chairman.

What's Alan Colman's mailing address?

Alan's mailing address filed with the SEC is 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, NV, 89014.

Insiders trading at VolitionRX Ltd

Over the last 12 years, insiders at VolitionRX Ltd have traded over $775,239 worth of VolitionRX Ltd stock and bought 1,908,474 units worth $44,487,770,972 . The most active insiders traders include Guy Archibald Innes, Cameron John Reynolds a Martin Charles Faulkes. On average, VolitionRX Ltd executives and independent directors trade stock every 43 days with the average trade being worth of $27,899. The most recent stock trade was executed by Guy Archibald Innes on 20 August 2024, trading 150,000 units of VNRX stock currently worth $100,500.

What does VolitionRX Ltd do?

volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.

Complete history of Alan Colman stock trades at VolitionRX Ltd

VolitionRX Ltd executives and stock owners

VolitionRX Ltd executives and other stock owners filed with the SEC include:

• Cameron Reynolds,
  President, Chief Executive Officer, Director
• Cameron Reynolds MBA,
  Founder, Group CEO, Pres & Director
• Jason Terrell,
  Chief Medical Officer and Head of US Operations
• Dr. Jason Bradley Terrell,
  Chief Medical Officer & Head of U.S. Operations
• David Vanston,
  Chief Financial Officer, Treasurer
• Jacob Micallef,
  Chief Scientific Officer
• Martin Faulkes,
  Executive Chairman of the Board
• Rodney Rootsaert,
  Corporate Secretary
• Dr. Martin Charles Faulkes Ph.D.,
  Exec. Chairman
• Dr. Jacob Vincent Micallef,
  Chief Scientific Officer
• Dr. Salvatore Thomas Butera,
  Chief Exec. Officer of Volition Veterinary Diagnostics Devel. LLC
• Scott Powell,
  IR Contact Officer
• Guy Innes,
  Independent Director
• Edward Futcher,
  Independent Director
• Alan Colman,
  Independent Director
• Phillip Barnes,
  Independent Director
• Gaetan Michel,
  Chief Executive Officer of Belgian Volition
• Jasmine Kway,
  Chief Executive Officer of Singapore Volition
• Nick Plummer,
  Group Gen. Counsel
• Scott Powell Ph.D.,
  Exec. VP of Investor Relations & CFO of Volition America Inc
• Dr. Mark Eccleston M.B.A., Ph.D.,
  Chief Technology Officer
• Dr. Gaetan Michel Ph.D.,
  Chief Operating Officer
• Terig Hughes,
  Group CFO & Treasurer
• Corp Ltd Cotterford Co Ltd ...,
  
• Richard Brudnick,
  
• Habib Skaff,
  Director
• David Matthew Kratochvil,
  Chief Financial Officer
• Rodney Gerard Concord Inter...,
  Secretary
• Nicholas Plummer,
  GC - Volition Diagnostics
• Ann Louise Batchelor,
  Group Chief Marketing Officer
• Kim Nguyen,
  
• Terig Hughes,
  Chief Financial Officer
• Mickie Henshall,
  
• Gael Forterre,
  Chief Commercial Officer
• Corp Ltd Hever Investments ...,
  
• Salvatore Thomas Butera,
  CEO - Volition Veterinary